Micro-X Limited (MX1) Fair Value & Analysis
Healthcare · AU · Market cap A$30.6M
Fair value as of: Jun 26, 2026
From 3 valuation models · updated 6 days ago
Fair value updated Jun 26, 2026 — revised from A$0.0500 to A$0.0749 (+49.8%) since Jun 24, 2026. Share price −10.3% over the past month.
Price vs Fair Value (12 months)
12‑month range A$0.0302 – A$0.1084 · fair‑value band A$0.0485 – A$0.1013 · the A$0.0330 price screens below the A$0.0749 fair value. As of Jun 26, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Micro-X Limited (MX1) currently trades at A$0.0330, while our model-based Fair Value estimate is A$0.0749 — implying the stock looks roughly 127.0% undervalued today. We read business quality at 27/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Over the trailing twelve months, Micro-X Limited generated revenue of A$16.9M at a net margin of -70.0%. Revenue grew 51.9% year over year. Net debt stands at A$3.3M. Fundamentals as of Jun 26, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
About the company
Micro-X Limited designs, develops, manufactures, and commercializes imaging products for healthcare, defense, and security markets through cold cathode X-ray technology. The company provides carbon nanotube-based X-ray products, including core X-ray tube and high-voltage generator components. It also provides Rover Plus for medical performance in a mobile system; Head CT, a standard ambulance or retrieval aircraft for stroke; Checkpoints, a modular passenger self-screening checkpoint for airports; Baggage scanner, a CT baggage scanner for passenger self-screening checkpoints; Argus, a wide-area scattered projection backscatter and miniaturized high-voltage generator; and space imaging solutions. The company operates in Australia, the United States, the Asia-Pacific, Europe, the Middle East, and Africa. Micro-X Limited was incorporated in 2011 and is based in Tonsley, Australia.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Micro-X Limited reported revenue of A$13.1M in FY2025 versus A$3.8M in FY2021, a compound +36.4%/yr. Reported net income was −A$13.9M in FY2025.
Is MX1 fairly valued? → Check now
Similar stocks
6 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| ABT ABT | 1,600 MXN | 1,231 MXN | -23% |
| Abbott Laboratories, ABTT34 | R$38.22 | R$30.39 | -20% |
| Stryker Corporation S1YK34 | R$77.83 | R$8.47 | -89% |
| Medtronic plc MDT | $80.25 | $74.40 | -7% |
| Boston Scientific Corporation B1SX34 | R$248.75 | R$221.81 | -11% |
| Edwards Lifesciences Corporation EW | $85.88 | $41.02 | -52% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Micro-X Limited (MX1) undervalued?
What is the fair value of MX1?
What is the quality score of MX1?
What is the revenue of Micro-X Limited (MX1)?
What is the net profit margin of MX1?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.